Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
54.80
-0.07 (-0.13%)
At close: Jan 28, 2026
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
0.98
Revenue / Employee
518.25K EUR
Employees
88,502
Market Cap
52.98B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Tian'an Technology Group | 2.12M |
Bayer Aktiengesellschaft News
- 2 days ago - Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada - Business Wire
- 2 days ago - Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention - Business Wire
- 7 days ago - Bayer Announces FDA's Orphan Drug Designation For OpCT-001 To Treat Retinitis Pigmentosa - Nasdaq
- 9 days ago - Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case - Nasdaq
- 9 days ago - Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases - Business Wire
- 10 days ago - Bayer: Timing Upside In 2025, More Upside Possible But Risky In 2026E (Downgrade) - Seeking Alpha
- 10 days ago - Bayer Shares Rise After U.S Supreme Court Agrees to Review Roundup Case - The Wall Street Journal
- 12 days ago - Bayer : U.S. Supreme Court To Review Durnell Case In Roundup Litigation - Nasdaq